<![CDATA[FDA Approves 1-Minute SC Mosunetuzumab for R/R Follicular Lymphoma]]>
The FDA has approved a subcutaneous (SC) formulation of mosunetuzumab (Lunsumio VELO; Genentech/Roche) for adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) after 2 or more lines of systemic therapy. Mosunetuzumab is a …